OncoMatch/Clinical Trials/NCT06051240
Lithium Treatment to Prevent Cognitive Impairment After Brain Radiotherapy
Is NCT06051240 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Lithium for cognitive impairment.
Treatment: Lithium — Randomized, placebo-controlled, double-blinded, parallel group clinical trial to investigate if 6 months of oral lithium tablets (S-lithium 0,5-1,0 mmol/l) will prevent cognitive decline after brain radiotherapy in pediatric brain tumor survivors. Primary outcome measure is Processing Speed Index (PSI) 2 years after start of study treatment.
Check if I qualifyExtracted eligibility criteria
Cancer type
Glioblastoma
Prior therapy
Must have received: radiation therapy — cranial/craniospinal
Lab requirements
Kidney function
cystatin c derived glomerular filtration rate >= 60
Cardiac function
no cardiac failure or heart disease, including brugada syndrome (or family history thereof)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify